Standard Issue Transfusion versus fresher red blood cell use in intensive care - a randomized controlled trial

Phase 3

Completed

• Conditions: Blood transfusion; Critically ill patients; Blood - Anaemia

• Registration Number: ACTRN12612000453886
• Lead Sponsor: Monash University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-04-23
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

Patients hospitalised in ICU with an anticipated ICU stay of at least 24 hours, in whom the decision has been made by medical staff to transfuse at least one RBC unit.

Exclusion Criteria

Age younger than 18

A previous RBC transfusion during the current hospital admission (including transfusion in another hospital for transferred patients)

Diagnosis of transplantation or hematologic diseases

Pregnancy

Cardiac surgery during the present hospital admission

Expected to die imminently (<24hrs)

The treating physician believes it is not in the best interest of the patient to be randomised in this trial.

Known objection to the administration of human blood products

Participation in a competing study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
This study aims to determine whether, compared to standard care, transfusion of the freshest available allogeneic RBC decreases mortality of patients admitted to ICU.[90 day mortality]

Secondary Outcome Measures

Name	Time	Method
Persistant Organ Dysfunction combined with death at day 28 defined as number of days requiring mechanical ventilation, renal replacement therapy and catecholamines.[day 28];Mortality[Day 28];Days alive and free of mechanical ventilation (post randomisation) at day 28[Day 28];Days alive and free of RRT post randomisation at day 28[Day 28];Blood stream infection rate in ICU post randomisation[While in ICU];Length of stay in ICU post randomisation[At ICU discharge];Proportion of patients who suffer at least one febrile non-haemolytic transfusion reaction in ICU[While in ICU];Quality of life (EQ5D) at 180 days[Day 180];Length of stay in hospital post randomisation[At hospital discharge]